发明名称 |
Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug |
摘要 |
Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix. |
申请公布号 |
US9456985(B2) |
申请公布日期 |
2016.10.04 |
申请号 |
US201514697891 |
申请日期 |
2015.04.28 |
申请人 |
UPSHER-SMITH LABORATORIES, INC. |
发明人 |
Wertz Christian F.;Jensen James S.;O'Neill Victoria Ann;Mahoney Sean B.;Berge Stephen M. |
分类号 |
A61K9/20;A61K31/44;A61K31/19;A61K31/13;A61K31/135;A61K31/46;A61K31/485;A61K31/138;A61K31/192 |
主分类号 |
A61K9/20 |
代理机构 |
Mueting, Raasch & Gebhardt, P.A. |
代理人 |
Mueting, Raasch & Gebhardt, P.A. |
主权项 |
1. A sustained-release oral pharmaceutical composition comprising within a single dosage form:
a hydrophilic matrix comprising a cellulose ether selected from the group consisting of a hydroxyalkyl cellulose, a carboxyalkyl cellulose, and a combination thereof; a therapeutically effective amount of a non-opioid amine-containing compound; and a salt of a non-steroidal anti-inflammatory drug (NSAID); wherein the non-opioid amine-containing compound and the salt of an NSAID are within the hydrophilic matrix; and wherein the composition exhibits a release profile with respect to the non-opioid amine-containing compound, wherein the release profile comprises a substantial portion that is representative of zero-order release kinetics under in vitro conditions as a result of dissolution of the hydrophilic matrix. |
地址 |
Maple Grove MN US |